CMND

0.903

3.56% 0.031

Handel nachbörslich: .90 -0.003 -0.33%

Clearmind Medicine Inc (CMND)

Überblick Nachrichten Preisverlauf Warum fällt CMND? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$0.872

Offen:

$0.8599

24-Stunden-Volumen:

32,239

Relative Volume:

0.14

Marktkapitalisierung:

$4.60M

Einnahmen:

Nettoeinkommen (Verlust:

$-6.78M

KGV:

-0.0211

EPS:

-42.6996

Netto-Cashflow:

$-4.67M

1W Leistung:

+0.34%

1M Leistung:

-4.14%

6M Leistung:

-37.72%

1J Leistung:

-42.85%

1-Tages-Spanne:

$0.85

$0.905

1-Wochen-Bereich:

$0.85

$0.91

52-Wochen-Spanne:

$0.80

$2.30

Clearmind Medicine Inc Stock (CMND) Company Profile

Firmenname

Clearmind Medicine Inc

Sektor

Healthcare (1166)

Branche

Biotechnology (655)

Telefon

Adresse

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

CMND's Discussions on Twitter

Vergleichen Sie CMND mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CMND Clearmind Medicine Inc	0.903	4.60M	0	-6.78M	-4.67M	-42.70
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten

Jun 16, 2025

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com

Jun 16, 2025

Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update - Defense World

Jun 16, 2025

Jun 13, 2025

Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants - Psychedelic Alpha

Jun 13, 2025

Jun 12, 2025

Clearmind Medicine Inc. (NASDAQ:CMND) Shares Acquired by Citadel Advisors LLC - Defense World

Jun 12, 2025

# Clearmind Medicine hires lobbying firm to advance psychedelic therapy By Investing.com - Investing.com South Africa

Jun 12, 2025

# Clearmind Medicine hires lobbying firm to advance psychedelic therapy - Investing.com Australia

Jun 12, 2025

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics - The Manila Times

Jun 12, 2025

Clearmind Medicine Partners with Leading Government Affairs Firm to Advance Psychedelic Therapeutics - Nasdaq

Jun 12, 2025

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic ... - Bluefield Daily Telegraph

Jun 12, 2025

Jun 05, 2025

Clearmind Medicine Announces Enrollment Of First Patient In Phase I/Iia Clinical Trial For Alcohol Use Disorder Treatment - marketscreener.com

Jun 05, 2025

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment - The Manila Times

Jun 05, 2025

Clearmind Medicine Inc. Begins Phase I/IIa Trial for CMND-100 to Treat Alcohol Use Disorder - Nasdaq

Jun 05, 2025

May 30, 2025

SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc. - Nasdaq

May 12, 2025

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times

May 12, 2025

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times

May 12, 2025

May 05, 2025

Stocks Under $1 To Watch: $NITO, $SPRC, $PNPNF, $NCNA, $PRSO – Multi-Sectors Momentum Building more inside… | FinancialContent - FinancialContent

May 05, 2025

Apr 28, 2025

Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.

Apr 28, 2025

Apr 25, 2025

Clearmind Medicine files patent for eating disorder treatment - Investing.com

Apr 25, 2025

SciSparc and Clearmind file patent for eating disorder treatment - Investing.com

Apr 25, 2025

Clearmind Medicine files patent for eating disorder treatment By Investing.com - Investing.com South Africa

Apr 25, 2025

SciSparc and Clearmind file patent for eating disorder treatment By Investing.com - Investing.com India

Apr 25, 2025

Psychedelic: Clearmind completes clinical site initiations for AUD trial - Yahoo Finance

Apr 25, 2025

SciSparc and Clearmind File Patent for Eating Disorder Treatment - TipRanks

Apr 25, 2025

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders - The Manila Times

Apr 25, 2025

SciSparc-Clearmind Collaboration Leads to Filing of - GlobeNewswire

Apr 25, 2025

Clearmind Medicine Inc. Files International Patent for Novel Treatment of Eating Disorders Using 3-MMC and PEA - Nasdaq

Apr 25, 2025

Novel Eating Disorder Treatment Patent Filed for 70M Patient Market | SPRC Stock News - Stock Titan

Apr 25, 2025

Apr 23, 2025

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites - The Manila Times

Apr 23, 2025

Clearmind Medicine Inc. Initiates Patient Enrollment for Phase I/IIa Clinical Trial in Alcohol Use Disorder - Nasdaq

Apr 23, 2025

Clearmind Medicine (NASDAQ:CMND) Stock Price Down 4.8% – Here’s Why - Defense World

Apr 23, 2025

Apr 22, 2025